6
INAF0209.TXT

INAF
Indofarma Tbk
Af          :
Sector Code : 53
Sector Name : PHARMACEUTICALS

(In thousand rupiah except Par Value, Closing Price and Ratios)

Financial Statement Date    : 30-Sep-2002
Fiscal Year Ends            : Dec
Months Covered in Income St : 9

Summary of Balance Sheet
  Receivables               :     235,875,179.72
  Inventories               :     419,277,983.25
  Current Assets            :     827,576,390.99
  Fixed Assets              :     126,329,212.31
  Other Asstes              :      14,810,799.10
  Total Assets              :     976,509,736.16
  Current Liabilities       :     425,854,345.84
  Longterm Liabiities       :       4,431,764.23
  Total Liabilities         :     430,286,110.08
  Authorized                :      10,000,000.00
  Paid-up Capital           :     309,926,750.00
  Par Value                 :                100
  Paid-up Capital Shares    :       3,099,267.50
  Retained Earnings         :     153,801,581.74
  Total Equity              :     538,828,687.92
  Minority Interest         :       7,394,938.16

Summary of Income Statement
  Total Sales               :     444,075,244.97
  Cost of Good Sold         :     211,794,969.63
  Gross Profit              :     232,280,275.34
  Operating Profit          :     134,316,018.04
  Other Income              :      -7,498,021.79
  Eearning Before Tax       :     126,817,996.25
  Tax                       :      38,568,588.73
  Net Income                :      88,567,388.01
  Closing Price             :             230.00

Per Share Data (Rp)
  Eps                       :              38.10
  Book Value                :             173.86

Financial Ratios
  Debt Equity Ratio (X)     :                .80
  Roa (%)                   :              12.09
  Roe (%)                   :              21.92
  Npm (%)                   :              26.59
  Opm (%)                   :              40.33

Cash Flow
  CF from Operating Activities                        :    -120,322,543.81
  CF from Investing Activities                        :     -31,437,153.32
  CF from Financing Activities                        :      79,588,747.61
  Net Increase in Cash & Cash Equivalent              :     -72,170,949.51
  Cash & Cash Equivalent at The Beginning of The Year :     120,038,378.16
  Cash & Cash Equivalent at The End of The Year       :      48,257,450.66

 
 
 
